LongBio Pharma is a biotech company located in Shanghai, China. The company, which was founded in 2018, is focused on autoimmune and rare diseases, serving patients and society. The co-founder of LongBio Pharma, Dr. Sun, Bill, Nai-chau, is also the co-founder of Tanox, with its IPO in Nasdaq at 2000 and acquired by Genentech in 2007. He is also the co-inventor of Omalizumab (Xolair®, Global sales is 3.6B USD in 2022), the first anti-IgE antibody approved by FDA.

LongBio Pharma aims to bring our drugs to both domestic and international markets with our partners, especially to bring patients with more affordable and high-quality bio-medicines. Our leading pipeline is a next generation of anti-IgE antibody (LP-003), which is about to start Phase III study in 2024Q1, and prepare for BLA in 2025H1. The second leading pipeline is a bifunctional complement inhibitor (LP-005) , which is in Phase I at present, intending to start Phase II/III in 2024Q2.